14:30 Thu 26 Jul 2018
Verona Pharma plc : Notice of Results
to Announce Interim Results for Six Months Ended and Provide Clinical Development UpdateVerona Pharma June 30, 2018
, (GLOBE NEWSWIRE) -- (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited financial results for the six months ended on .
will host an investment community conference call at ( British ) on to discuss the six months financial results and provide a clinical development update.
Analysts and investors may participate in the conference call by utilizing the conference ID: 7830929 and dialing the following numbers:
Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of website at and clicking on the "Events and presentations" link.
A webcast replay of the conference call (audio) will be available for 30 days on the "Investors" page of website at .
About
is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
- 800-458-4121 or 929-477-0324 for callers in
the United States - 0800 279 7204 or 44 (0)330 336 9411 for callers in the
United Kingdom - 0800 101 1732 or 49 (0)69 2222 2018 for calls in
Germany
Tel: +44 (0)20 3283 4200 | |
, Chief Executive Officer | info@veronapharma.com |
(Nominated Adviser and Broker) | Tel: +44 (0) 20 7710 7600 |
/ / | |
FTI Consulting ( Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 |
/ | veronapharma@fticonsulting.com |
(US Media and Investor enquiries) | |
Tel: +1 203-682-8251 James.Heins@icrinc.com | |
Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com |
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE